https://www.gov.uk/government/publications/staying-put-arrangements-for-care-leavers-aged-18-years-and-above<\/a>. This means young people can continue to benefit from a stable and secure family setting, preparing for independence at a more gradual pace and moving into independent living when they are ready, rather than facing a cliff-edge on reaching age 18.<\/p>To support local authorities to implement Staying Put we have provided £68.35 million to date. Funding for 2019/20 will be £23.77 million, and funding beyond 2020 will be subject to future spending reviews.<\/p>
The latest data show that for the year ending March 2018, 55% of those ceasing to be looked after in a foster placement on their 18th birthday stayed put with their former foster carer, which is an increase of 4% on the previous year. Furthermore, 31% of 19 year-olds were still with former foster carers on their 19th birthday, and 26% of 20 year-olds still with former foster carers on their 20th birthday. Again, these were both increases on the previous year.<\/p>
<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
}
, "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
, "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
, "dateOfAnswer" : {"_value" : "2018-11-22", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-11-22T15:52:47.017Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "60"}
, "answeringDeptShortName" : {"_value" : "Education"}
, "answeringDeptSortName" : {"_value" : "Education"}
, "date" : {"_value" : "2018-11-15", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Foster Care: Care Leavers"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Education, what steps the Government is taking to support foster carers to assist their former fostered children when they leave care.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4648", "label" : {"_value" : "Biography information for Laura Smith"}
}
, "tablingMemberConstituency" : {"_value" : "Crewe and Nantwich"}
, "tablingMemberPrinted" : [{"_value" : "Laura Smith"}
], "uin" : "191981"}
, {"_about" : "http://data.parliament.uk/resources/1007757", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1007757/answer", "answerText" : {"_value" : "
The United Kingdom\u2019s position on medicines regulation remains clear. We want to retain a close working partnership with the European Union to ensure that medicines remain available to UK patients in a safe and timely manner. We have been clear that this involves us making sure our regulators continue to work together, as they do with regulators internationally. As the Prime Minister has said, we intend to to explore with the EU the terms on which the UK could remain part the European Medicines Agency.<\/p>
<\/p>
Until we can be certain of the outcome of Brexit negotiations our duty as a responsible Government is to prepare for all eventualities, including \u2018no deal\u2019. On 23 August 2018, therefore, the Department wrote to all pharmaceutical companies that supply the United Kingdom with prescription only or pharmacy medicines from, or via, the European Union/European Economic Area, asking them to ensure they have a minimum of six weeks\u2019 additional supply in the UK, over and above their business as usual operational buffer stocks, by 29 March 2019 in the event of a no-deal scenario.<\/p>
<\/p>
Since then, we have received very good engagement from industry who share our aims of ensuring continuity of medicines supply for patients is maintained and able to cope with any potential delays at the border that may arise in the short term in the event of a no-deal Brexit.<\/p>
<\/p>
We understand that the medicine Keppra is important to many people in this country. However, the Department recognises that through its medicines supply contingency programme it is requesting sensitive commercial information from pharmaceutical companies. To reassure participating companies, we have committed to treating all information received confidentially, securely and to using it only for the purposes of the Department\u2019s programme. That means not introducing information about a company, specific medicine or their supply routes into the public domain.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2018-11-22", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-11-22T11:54:10.717Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-11-15", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Levetiracetam"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will make an assessment of the effect of the UK leaving the EU on the availability of Keppra for people with epilepsy.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4648", "label" : {"_value" : "Biography information for Laura Smith"}
}
, "tablingMemberConstituency" : {"_value" : "Crewe and Nantwich"}
, "tablingMemberPrinted" : [{"_value" : "Laura Smith"}
], "uin" : "191984"}
, {"_about" : "http://data.parliament.uk/resources/1007759", "AnsweringBody" : [{"_value" : "Ministry of Housing, Communities and Local Government"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1007759/answer", "answerText" : {"_value" : "
I received representations on unitarisation in Buckinghamshire from the following local business organisations: Buckinghamshire Business First, Buckinghamshire Business Group, Chiltern Chamber of Commerce, Thames Valley Chamber of Commerce; 18 individual local businesses also made representations. Information about grant funding and support provided by local authorities to business organisations is not held centrally. The Local Government Transparency Code 2015 requires local authorities to publicise specified data on financial transactions including publishing details of all grants to voluntary, community and social enterprise organisations.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4483", "label" : {"_value" : "Biography information for Rishi Sunak"}
}
, "answeringMemberConstituency" : {"_value" : "Richmond (Yorks)"}
, "answeringMemberPrinted" : {"_value" : "Rishi Sunak"}
, "dateOfAnswer" : {"_value" : "2018-11-21", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-11-21T13:51:10.943Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "7"}
, "answeringDeptShortName" : {"_value" : "Housing, Communities and Local Government"}
, "answeringDeptSortName" : {"_value" : "Housing, Communities and Local Government"}
, "date" : {"_value" : "2018-11-15", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Unitary Councils: Buckinghamshire"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Housing, Communities and Local Government, pursuant to the Written Statement of 1 November 2018, Local Government Update, HCWS 1058, from which businesses and organisations in Buckinghamshire he has received representations on local government reorganisation; and what information his Department holds on the amount of grant funding or financial support those businesses and organisations have received from Buckinghamshire County Council in the last three years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/18", "label" : {"_value" : "Biography information for Dame Cheryl Gillan"}
}
, "tablingMemberConstituency" : {"_value" : "Chesham and Amersham"}
, "tablingMemberPrinted" : [{"_value" : "Dame Cheryl Gillan"}
], "uin" : "191992"}
, {"_about" : "http://data.parliament.uk/resources/1007767", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1007767/answer", "answerText" : {"_value" : "
The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance for the National Health Service on the use of Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA).<\/p>
<\/p>
NICE is in discussion with Biogen (the company that manufactures Spinraza) to determine if there are any commercial flexibilities that could support the company in putting forward a cost-effective price in order for NICE to recommend use of the drug as a clinically and cost-effective use of NHS resources.<\/p>
<\/p>
NHS England has published an Interim Policy Statement determining the circumstances in which existing patients will be supported to access Spinraza through the Expanded Access Programme (EAP) scheme sponsored by Biogen. The policy statement enables existing patients with type 1 SMA to access Spinraza in advance of NICE\u2019s guidance, although the company has now withdrawn the EAP for newly diagnosed patients.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2018-11-22", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-11-22T15:13:09.58Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-11-15", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Nusinersen"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what progress NHS England, Biogen and NICE have made in discussions on a managed access agreement for the use of Spinraza for the treatment of spinal muscular dystrophy.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4249", "label" : {"_value" : "Biography information for Anne Marie Morris"}
}
, "tablingMemberConstituency" : {"_value" : "Newton Abbot"}
, "tablingMemberPrinted" : [{"_value" : "Anne Marie Morris"}
], "uin" : "191928"}
, {"_about" : "http://data.parliament.uk/resources/1007777", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1007777/answer", "answerText" : {"_value" : "
The NHS Cancer Programme is working to improve access to cancer nurse specialists (CNSs) for all cancer patients when they need it, including those with secondary breast cancer.<\/p>
<\/p>
We are committed to rolling out the recovery package to every cancer patient by 2020. The recovery package is a set of four interventions designed to help patients and clinicians assess a patient\u2019s holistic needs, including physical and emotional needs, at appropriate time points through their cancer journey, as needs do change especially when a person is diagnosed with secondary cancer. A personalised care and support plan to meets these needs should be agreed, ensuring signposting and referral to the right support and care services is made, and also helping to empower patients to independently manage their own health, with advice and support.<\/p>
<\/p>
NHS England is committed to giving more patients access to a CNS or other specialist from diagnosis onwards to guide them through treatment options and ensure they receive appropriate information and support. In their first Cancer Workforce Plan, which was published in December 2017, Health Education England committed to supporting the expansion of CNSs by developing national competencies and a clear route into training. This will ensure that every patient has access to a CNS or other support worker by 2021.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2018-11-22", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-11-22T15:20:10.943Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-11-15", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Breast Cancer"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will introduce a secondary support package covering breast cancer care to include (a) access to a dedicated clinical nurse specialist, (b) an assessment of physical and emotional needs at (i) diagnosis and (ii) through treatment and referral and (c) signposting to tailored, specialist support services.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/478", "label" : {"_value" : "Biography information for Lord Field of Birkenhead"}
}
, "tablingMemberConstituency" : {"_value" : "Birkenhead"}
, "tablingMemberPrinted" : [{"_value" : "Frank Field"}
], "uin" : "191871"}
, {"_about" : "http://data.parliament.uk/resources/1007780", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1007780/answer", "answerText" : {"_value" : "
The Government has no plans to run such a national campaign at this time. The Department is working closely with NHS England and the Government Equalities Office in the implementation of the LGBT Action Plan, which was published in July 2018. This will include the recruitment of a National Adviser who will work to lead improvements to LGBT healthcare.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"}
}
, "answeringMemberConstituency" : {"_value" : "Thurrock"}
, "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"}
, "dateOfAnswer" : {"_value" : "2018-11-22", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-11-22T11:50:59.533Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-11-15", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Health Services: LGBT+ People"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference Stonewall's report entitled LGBT in Britain: Health Report, published in November 2018, if he will ask NHS England to run a national campaign to (a) tackle (i) homophobic, (ii) biphobic and (iii) transphobic discrimination in healthcare services and (b) encourage reporting of such discrimination.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4267", "label" : {"_value" : "Biography information for Sarah Champion"}
}
, "tablingMemberConstituency" : {"_value" : "Rotherham"}
, "tablingMemberPrinted" : [{"_value" : "Sarah Champion"}
], "uin" : "191935"}
, {"_about" : "http://data.parliament.uk/resources/1007787", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1007787/answer", "answerText" : {"_value" : "
The Department\u2019s National Institute for Health Research (NIHR) welcomes funding applications for research into any aspect of human health, including Parkinson\u2019s disease and related illness. It is not usual practice to ring-fence funds for particular topics or conditions. Applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.<\/p>
<\/p>
The following table shows NIHR research into mental health interventions for people with Parkinson\u2019s disease who suffer anxiety and or depression over the last five years is approximately £4.9 million. This includes funding for research projects and clinical trials through the NIHR Clinical Research Network:<\/p>
<\/p>